Antibody Drug Conjugate News and Research

RSS
Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

UKB resident awarded the C. E. Alken Prize for outstanding scientific uro-oncological research

UKB resident awarded the C. E. Alken Prize for outstanding scientific uro-oncological research

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Comprehensive analysis outlines the potential toxicities of antibody drug conjugates

Comprehensive analysis outlines the potential toxicities of antibody drug conjugates

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

Multiple ischemic strokes and pulmonary embolism found in COVID-19 patient

Multiple ischemic strokes and pulmonary embolism found in COVID-19 patient

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Trastuzumab deruxtecan treatment maintains quality of life in HER2-low metastatic breast cancer patients

Addition of brentuximab vedotin to chemotherapy has a positive impact for patients with Hodgkin lymphoma

Addition of brentuximab vedotin to chemotherapy has a positive impact for patients with Hodgkin lymphoma

Spirea raises £2.4M ($3M) to develop antibody drug conjugates   in cancer

Spirea raises £2.4M ($3M) to develop antibody drug conjugates in cancer

At US hospitals, a drug mix-up is just a few keystrokes away

At US hospitals, a drug mix-up is just a few keystrokes away

Study demonstrates multinuclear MRI is sensitive to functional pulmonary changes in the follow up of patients hospitalized with COVID-19

Study demonstrates multinuclear MRI is sensitive to functional pulmonary changes in the follow up of patients hospitalized with COVID-19

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

NK cells complexed with bispecific antibody elicit high response rate in patients with resistant lymphomas

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

$1.3 million in NIH funding to enable drug delivery technology research

$1.3 million in NIH funding to enable drug delivery technology research

MGH researchers discover how triple-negative breast cancer can evade powerful drugs

MGH researchers discover how triple-negative breast cancer can evade powerful drugs

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

New antibody-drug conjugates also kill non-targeted neighboring tumor cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.